Response Criteria in Urologic Malignancies

  • F. M. Torti
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 85)


The recognition of a response to treatment in prostatic carcinoma is not qualitatively different than that in other solid tumors; nonetheless, the preponderance of bone as a site of metastases in prostate cancer makes effective measurement of response difficult. In other disease sites, such as colorectal cancer or lung cancer, inability to detect early and quantitative changes on bone scan (i.e., 25% versus 50% improvement) are of less clinical importance. In these tumors there are indicator lesions in lung, soft tissue, etc. which can be easily measured and quantitated. In contrast, in prostatic carcinoma, for the vast majority of patients, bone is the only site of metastatic disease and the dominant site of symptomatic disease.


Acid Phosphatase Prostatic Carcinoma Mature Teratoma Prostatic Acid Phosphatase Immature Teratoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bagshaw MA (1978) Radiation therapy for cancer of the prostate. In: Skinner DG, de Kernion JB (eds) Genitourinary cancer. Saunders, New York, p 358Google Scholar
  2. 2.
    Byar DP (1977) VACURG studies on prostatic cancer and its treatment. In: Tannenbaum M (ed) Urologie pathology: the prostate. Lea & Febiger, Philadelphia, pp 241–267Google Scholar
  3. 3.
    Citrin DL, Cohen AI, Harberg J, Schlise S, Hougen C, Benson (1981) Systemic treatment of advanced prostatic cancer: development of a new system for defining response. J Urol 125:224–227PubMedGoogle Scholar
  4. 4.
    Citrin DL, Hougen C, Zweibel W, Schlise S, Pruitt B, Ershler W, Davis TE, Harberg J, Cohen AI (1981) The use of serial bone scans in assessing response of bone metastases to systemic treatment. Cancer 47:680–685PubMedCrossRefGoogle Scholar
  5. 5.
    Einhorn LH, Williams SD, Mandelbaum I, Donohur JP (1981) Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 48: 904–908PubMedCrossRefGoogle Scholar
  6. 6.
    Foti AG, Cooper JF, Hershman H, Malvaez RR (1977) Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N Engl J Med 297:1357–1362PubMedCrossRefGoogle Scholar
  7. 7.
    Galasko CSB, Doyle FM (1972) The response to therapy of skeletal metastases from mammary cancer: assessment of scintigraphy. Br J Surg 59:85–88PubMedCrossRefGoogle Scholar
  8. 8.
    Hardy JG, Kulatilake AE, Wastie ML (1980) An index for monitoring bone metastases from carcinoma of the prostate. Br J Radiol 53:869–873PubMedCrossRefGoogle Scholar
  9. 9.
    Henneberry M, Carter MF, Neiman HL (1979) Estimation of prostatic size by suprapubic ultrasonography. J Urol 121:615–616PubMedGoogle Scholar
  10. 10.
    Hovsepian JA, Byar DP and the VACURG (1978) Quantitative radiology of responses to endocrine therapy in stage 4 adenocarcinoma of the prostate. Proc AACR and ASCO 19:307Google Scholar
  11. 11.
    Ishibe T, Usui T, Nihira H (1974) Prognostic usefulness of serum acid phosphatase levels in carcinoma of the prostate. J Urol 112:237–240PubMedGoogle Scholar
  12. 12.
    Johnson DE, Scott WW, Gibbons RP, Prout GR, Schmidt JD, Murphy GP (1976) Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma. Urology 8:123–126PubMedCrossRefGoogle Scholar
  13. 13.
    Mooppan MMU, Wax SH, Kim H, Wang JC, Tobin MS (1980) Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate. J Urol 123:694–696PubMedGoogle Scholar
  14. 14.
    Murphy GP, Reynoso G, Kenny GM, Gaeta JF (1969) Comparison of total and prostatic fraction serum acid phosphatase levels in patients with differentiated and undifferentiated prostatic carcinoma. Cancer 23:1309–1314PubMedCrossRefGoogle Scholar
  15. 15.
    Peeling WB, Griffiths GJ, Evans KT, Roberts EE (1979) Diagnosis and staging of prostatic cancer by transrectal ultrasonography. A preliminary study. Br J Urol 51:565–569PubMedCrossRefGoogle Scholar
  16. 16.
    Pistenma DA, McDougall IR, Kriss JP (1975) Screening for bone metastases. Are only scans necessary? JAMA 231:46–50CrossRefGoogle Scholar
  17. 17.
    Pollen JJ, Gerber K, Ashburn WL, Schmidt JD (1981) Nuclear bone imaging in metastatic cancer of the prostate. Cancer 47:2585–2594PubMedCrossRefGoogle Scholar
  18. 18.
    Pollen JJ, Shlaer (1979) Osteoblastic response to successful treatment of metastatic cancer of the prostate. AJR 132:927–931PubMedGoogle Scholar
  19. 19.
    Quinones GR, Rohner TJ, Drago JR, Demers LM (1981) Will prostatic acid phosphatase determination by radioimmunoassay increase the diagnosis of early prostatic cancer? J Urol 125:361–364PubMedGoogle Scholar
  20. 20.
    Resnick MI, Willard JW, Boyce WH (1980) Transrectal ultrasonography in the evaluation of patients with prostatic carcinoma. J Urol 124:482–484PubMedGoogle Scholar
  21. 21.
    Resnick MI, Willard JW, Boyce WH (1981) Ultrasonic evaluation of the prostatic nodule. J Urol 120:86–89Google Scholar
  22. 22.
    Shafer RB, Reinke DB (1977) Contribution of the bone scan, serum acid and alkaline phosphatase, and the radiographic bone survey to the management of newly-diagnosed carcinoma of the prostate. Clin Nucl Med 2:200–203CrossRefGoogle Scholar
  23. 23.
    Slack NH, Mittelman A, Brady MF, Murphy GP (1980) The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer. Cancer 46: 2393–2402PubMedCrossRefGoogle Scholar
  24. 24.
    Subramanian G, McAfee JG, Bell EG, Blair RJ, O’Mara RE (1972) 99mTc-labeled polyphosphate as a skeletal imaging agent. Radiology 102:701–704PubMedGoogle Scholar
  25. 25.
    Torti FM, Carter SK (1980) The chemotherapy of prostatic carcinoma. Ann Intern Med 92:681–689PubMedGoogle Scholar
  26. 26.
    Vihko P, Lukkarinen, Kontturi M, Vihko R (1981) Effectiveness of radioimmunoassay of human prostate-specific acid phosphatase in the diagnosis and follow-up of therapy in prostatic carcinoma. Cancer Res 41:1180–1183PubMedGoogle Scholar
  27. 27.
    Vugrin D, Whitmore WF, Sogani PC, Bains M, Herr HW, Golbey RB (1981) Combined chemotherapy and surgery in treatment of advanced germ-cell tumors. Cancer 47:2228–2231PubMedCrossRefGoogle Scholar
  28. 28.
    Wantanabe H, Igari D, Tanahasi Y, Harada K, Saitoh M (1975) Development and application of new equipment for transrectal ultrasonography. J Clin Ultrasound 2:91–98CrossRefGoogle Scholar
  29. 29.
    Watson R, Tang DB (1980) The predictive value of prostatic acid phosphatase as a screening test for prostatic cancer. N Engl J Med 303:497–499PubMedCrossRefGoogle Scholar
  30. 30.
    Yagoda A, Watson RC, Natale RB, Barzell W, Sogani P, Grabstald H, Whitmore WF (1979) A critical analysis of response criteria in patients with prostatic cancer treated with cis-diammmedichloride platinum II. Cancer 44:1553–1562PubMedCrossRefGoogle Scholar
  31. 31.
    Yam LT (1974) Clinical significance of the human acid phosphatases. Am J Med 56:604–616PubMedCrossRefGoogle Scholar
  32. 32.
    Yano Y, McRae J, Van Dyke DC, Anger HO (1973) Technetium-99m-labeled stannous ethane-l-hydroxy-1 1-diphosphonate: a new bone scanning agent. J Nucl Med 14: 73PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • F. M. Torti
    • 1
  1. 1.Division of Medical OncologyStanford University Medical CenterPalo AltoUSA

Personalised recommendations